Analyzing 57,910 weighted hospitalizations from the National Inpatient Sample, this value-of-care framework compared intra-aortic balloon pumps (IABP) and percutaneous left ventricular assist devices (pLVAD) in critically ill patients. Mean hospital charges reached $403,731 for pLVAD versus $320,769 for IABP — an $83,000 gap. Both devices achieved better-than-expected risk-adjusted mortality (observed-to-expected ratio 0.92), yet both exceeded predicted costs, with IABP showing 41% cost inflation above expectations. In-hospital mortality exceeded 30% across all regions, with the West incurring highest costs and the Midwest the lowest.
This finding lands in a contested space. pLVADs, particularly Impella devices, have proliferated rapidly in cardiogenic shock management despite weak randomized trial evidence — the landmark ISAR-SHOCK and IMPRESS trials failed to demonstrate mortality benefit over IABP, and the more recent RECOVER IV trial landscape remains unsettled. This retrospective national analysis reinforces that concern at scale, suggesting the cost-outcome ratio for pLVAD has not improved as adoption surged. The 30%-plus mortality floor for both strategies underscores how sick this population remains regardless of device choice.
Critical limitations apply: this is an administrative database study, meaning device selection bias, operator experience, and institutional volume cannot be adequately controlled. Causal inference is impossible. As a preprint posted on medRxiv and not yet peer-reviewed, these conclusions may shift substantially after expert scrutiny. Still, for health systems evaluating device procurement and clinical protocols, this analysis offers a timely, population-level value signal that incremental pLVAD adoption may not be cost-justified.